Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of tigulixostat versus allopurinol in gout with hyperuricemia
2022-501421-20-00Phase 3Completed
- Sponsor
- LG Chem
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of tigulixostat in gout and hyperuricemia (3 arms), sponsored by LG Chem. Primary endpoint: Sustained serum uric acid <6.0 mg/dL at Months 4, 5, and 6. Started Dec 2023; status: completed.
02
Drugs
tigulixostat
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on 2022-501421-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501421-20-00.